Organizational aspects of implementation pharmacogenetic testing in the treatment and prevention practice multidisciplinary hospital
Abstract
About the Authors
I. V. KukesRussian Federation
V. N. Shan
Russian Federation
M. K. Alimuradov
Russian Federation
A. V. Semenov
Russian Federation
V. M. Ruseykin
Russian Federation
D. A. Sychev
Russian Federation
References
1. Тарифы медико-экономических стандартов для оплаты по системе обязательного медицинского страхования, актуальные на ноябрь 2011 года (последняя версия).
2. Eckman M.H., Rosand J., Greenberg S.M., Gage B.F. Costeffectiveness of using pharmacogenetic information in warfarin dosing for patientswithnonvalvularatrial fibrillation. // Ann Intern Med. 2009. Jan 20;150(2):73-83.
3. Eriksson N., Wadelius M. Prediction of warfarin dose: why, when and how? // Pharmacogenomics March 2012. Vol. 13. No. 4. Pages 429-440. DOI 10.2217/pgs.11.184 (doi:10.2217/ pgs.11.184).
Review
For citations:
Kukes I.V., Shan V.N., Alimuradov M.K., Semenov A.V., Ruseykin V.M., Sychev D.A. Organizational aspects of implementation pharmacogenetic testing in the treatment and prevention practice multidisciplinary hospital. Journal Biomed. 2012;1(4):124-126. (In Russ.)